 Alice Soragni
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organoids | 7 | 2024 | 133 | 2.980 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 875 | 1.200 |
Why?
| | Antineoplastic Agents | 5 | 2025 | 2195 | 1.030 |
Why?
| | Neoplasms | 4 | 2025 | 2804 | 0.990 |
Why?
| | Sarcoma | 2 | 2025 | 194 | 0.920 |
Why?
| | Neurofibroma | 1 | 2024 | 5 | 0.860 |
Why?
| | Bioprinting | 1 | 2023 | 35 | 0.760 |
Why?
| | Chordoma | 1 | 2022 | 17 | 0.720 |
Why?
| | Cervix Uteri | 1 | 2021 | 51 | 0.690 |
Why?
| | Histocytochemistry | 1 | 2020 | 80 | 0.650 |
Why?
| | Tissue Culture Techniques | 1 | 2019 | 82 | 0.580 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 161 | 0.570 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 974 | 0.560 |
Why?
| | Precision Medicine | 2 | 2021 | 444 | 0.560 |
Why?
| | Protein Kinase Inhibitors | 2 | 2025 | 963 | 0.520 |
Why?
| | Skin Neoplasms | 1 | 2024 | 869 | 0.500 |
Why?
| | Social Media | 1 | 2019 | 166 | 0.490 |
Why?
| | Rhabdomyosarcoma | 2 | 2026 | 63 | 0.430 |
Why?
| | Sarcoma, Ewing | 2 | 2026 | 100 | 0.430 |
Why?
| | Eosinophils | 2 | 2024 | 325 | 0.410 |
Why?
| | Bone Neoplasms | 2 | 2026 | 249 | 0.390 |
Why?
| | Biomedical Research | 1 | 2019 | 699 | 0.390 |
Why?
| | alpha-Synuclein | 4 | 2013 | 44 | 0.360 |
Why?
| | Cell Proliferation | 2 | 2019 | 2542 | 0.360 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 539 | 0.350 |
Why?
| | Amyloid | 4 | 2013 | 96 | 0.320 |
Why?
| | Prions | 5 | 2011 | 51 | 0.320 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 586 | 0.310 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1524 | 0.300 |
Why?
| | Copper | 1 | 2008 | 115 | 0.270 |
Why?
| | tau Proteins | 1 | 2008 | 98 | 0.270 |
Why?
| | Fungal Proteins | 4 | 2011 | 141 | 0.250 |
Why?
| | Humans | 21 | 2026 | 143560 | 0.240 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2026 | 23 | 0.240 |
Why?
| | MyoD Protein | 1 | 2026 | 32 | 0.240 |
Why?
| | Small Ubiquitin-Related Modifier Proteins | 1 | 2025 | 15 | 0.230 |
Why?
| | Sarcoma, Synovial | 1 | 2025 | 22 | 0.230 |
Why?
| | Muscle Development | 1 | 2026 | 115 | 0.230 |
Why?
| | Soft Tissue Neoplasms | 1 | 2025 | 122 | 0.210 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2026 | 374 | 0.210 |
Why?
| | Neurofibromatosis 1 | 1 | 2024 | 55 | 0.210 |
Why?
| | Interferometry | 1 | 2023 | 6 | 0.200 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 213 | 0.200 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1043 | 0.190 |
Why?
| | DNA, Mitochondrial | 1 | 2024 | 211 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2023 | 198 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2026 | 354 | 0.190 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 431 | 0.180 |
Why?
| | Drug Discovery | 1 | 2022 | 149 | 0.170 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 5 | 2010 | 347 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 686 | 0.160 |
Why?
| | Information Dissemination | 2 | 2019 | 211 | 0.160 |
Why?
| | Lipid Bilayers | 3 | 2024 | 103 | 0.150 |
Why?
| | Cell Line | 2 | 2015 | 2897 | 0.150 |
Why?
| | Animals | 9 | 2026 | 38010 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 574 | 0.150 |
Why?
| | Social Networking | 1 | 2019 | 36 | 0.150 |
Why?
| | Publications | 1 | 2019 | 48 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1282 | 0.140 |
Why?
| | Mutation | 4 | 2026 | 4053 | 0.140 |
Why?
| | Peer Review | 1 | 2018 | 46 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2019 | 283 | 0.130 |
Why?
| | Cell Membrane | 2 | 2024 | 708 | 0.130 |
Why?
| | Cell Survival | 1 | 2019 | 1136 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2018 | 202 | 0.120 |
Why?
| | Secretory Vesicles | 1 | 2015 | 24 | 0.110 |
Why?
| | Cellulitis | 1 | 2015 | 55 | 0.110 |
Why?
| | Amino Acid Sequence | 5 | 2010 | 2165 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 732 | 0.110 |
Why?
| | Podospora | 2 | 2011 | 2 | 0.100 |
Why?
| | Molecular Sequence Data | 5 | 2010 | 2942 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3380 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 394 | 0.100 |
Why?
| | Communication | 1 | 2019 | 953 | 0.100 |
Why?
| | Eosinophilia | 1 | 2015 | 225 | 0.090 |
Why?
| | Signal Transduction | 1 | 2026 | 5214 | 0.090 |
Why?
| | Quality of Life | 1 | 2024 | 3080 | 0.090 |
Why?
| | Nanotechnology | 1 | 2013 | 126 | 0.090 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 369 | 0.090 |
Why?
| | Microscopy | 1 | 2013 | 156 | 0.090 |
Why?
| | Congo Red | 1 | 2011 | 10 | 0.090 |
Why?
| | Dermatitis, Atopic | 1 | 2015 | 333 | 0.090 |
Why?
| | Biopolymers | 1 | 2011 | 33 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4522 | 0.080 |
Why?
| | Fusarium | 1 | 2010 | 4 | 0.080 |
Why?
| | Protein Binding | 4 | 2013 | 2261 | 0.080 |
Why?
| | Escherichia coli | 1 | 2015 | 834 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2194 | 0.080 |
Why?
| | Protein Folding | 2 | 2010 | 277 | 0.080 |
Why?
| | Skin | 1 | 2015 | 774 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2026 | 1487 | 0.070 |
Why?
| | Protein Conformation | 2 | 2010 | 942 | 0.070 |
Why?
| | Nanoparticles | 1 | 2015 | 504 | 0.070 |
Why?
| | Immunity, Innate | 1 | 2015 | 861 | 0.070 |
Why?
| | Female | 3 | 2024 | 77251 | 0.070 |
Why?
| | Chromatography, Gel | 1 | 2008 | 129 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2015 | 1125 | 0.070 |
Why?
| | Calorimetry | 1 | 2008 | 71 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4182 | 0.070 |
Why?
| | Selenoprotein W | 1 | 2007 | 1 | 0.070 |
Why?
| | 14-3-3 Proteins | 1 | 2007 | 16 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2026 | 3611 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2022 | 11365 | 0.060 |
Why?
| | Models, Molecular | 2 | 2010 | 1622 | 0.060 |
Why?
| | Operator Regions, Genetic | 1 | 2005 | 8 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2026 | 65 | 0.060 |
Why?
| | Helicobacter pylori | 1 | 2005 | 44 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 75 | 0.060 |
Why?
| | Mice | 4 | 2026 | 18378 | 0.060 |
Why?
| | Ubiquitination | 1 | 2025 | 108 | 0.060 |
Why?
| | Protein Structure, Tertiary | 3 | 2011 | 863 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 6043 | 0.050 |
Why?
| | Extracellular Traps | 1 | 2024 | 54 | 0.050 |
Why?
| | CpG Islands | 1 | 2024 | 166 | 0.050 |
Why?
| | Peptides | 1 | 2009 | 976 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 232 | 0.050 |
Why?
| | Trans-Activators | 1 | 2005 | 402 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2026 | 941 | 0.050 |
Why?
| | Middle Aged | 1 | 2024 | 35342 | 0.050 |
Why?
| | Adult | 1 | 2024 | 40013 | 0.040 |
Why?
| | Microscopy, Fluorescence | 2 | 2013 | 420 | 0.040 |
Why?
| | Child | 3 | 2025 | 22725 | 0.040 |
Why?
| | Protein Multimerization | 2 | 2010 | 205 | 0.040 |
Why?
| | DNA Methylation | 1 | 2024 | 667 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2011 | 382 | 0.030 |
Why?
| | Amino Acid Substitution | 2 | 2011 | 311 | 0.030 |
Why?
| | Male | 1 | 2024 | 71500 | 0.030 |
Why?
| | Computer Simulation | 2 | 2011 | 1028 | 0.030 |
Why?
| | Binding Sites | 2 | 2011 | 1325 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2009 | 1369 | 0.030 |
Why?
| | Acetates | 1 | 2013 | 82 | 0.020 |
Why?
| | Thiophenes | 1 | 2013 | 128 | 0.020 |
Why?
| | Surface Properties | 1 | 2013 | 413 | 0.020 |
Why?
| | Polymerization | 1 | 2011 | 128 | 0.020 |
Why?
| | Lentivirus | 1 | 2011 | 60 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2011 | 368 | 0.020 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2011 | 177 | 0.020 |
Why?
| | Solutions | 1 | 2010 | 168 | 0.020 |
Why?
| | Macromolecular Substances | 1 | 2010 | 224 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 175 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 397 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2010 | 367 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 488 | 0.020 |
Why?
| | Selenocysteine | 1 | 2007 | 5 | 0.020 |
Why?
| | Structural Homology, Protein | 1 | 2007 | 26 | 0.020 |
Why?
| | Thioredoxins | 1 | 2007 | 32 | 0.020 |
Why?
| | Protein Structure, Quaternary | 1 | 2007 | 120 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2007 | 226 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2013 | 576 | 0.020 |
Why?
| | DNA Footprinting | 1 | 2005 | 33 | 0.010 |
Why?
| | Urease | 1 | 2005 | 13 | 0.010 |
Why?
| | Protein Subunits | 1 | 2005 | 229 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 1091 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5610 | 0.010 |
Why?
| | Repressor Proteins | 1 | 2005 | 438 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2199 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1263 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2005 | 944 | 0.010 |
Why?
| | Brain | 1 | 2011 | 2892 | 0.010 |
Why?
|
|
Soragni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|